Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "Randomized Phase 3 GASTFOX Study - 5-fluorouracil & Oxaliplatin +/- Docetaxel in the 1L Treatment of HER2- Locally Advanced Unresectable/Metastatic Gastric/GEJ Adenocarcinoma"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Aziz Zaanan
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Aziz Zaanan
Login to view comments.
Click here to Login
Gastrointestinal